YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Key Points Interested in Kodiak Sciences Inc.? Here are five stocks we like better. Three small-cap biotechs, Kodiak Sciences, Capricor Therapeutics, and Invivyd, face binary clinical trial or FDA decisions before the end of 2026. Kodiak's…
NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an aggregate of 277,500 shares of its comm…
NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 shares of its common…
LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19 vaccine Depending on study recr…
Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ stocks under $5 to buy right now. On May 14, Invivyd reported earnings for Q1 2026, highlighted by $13.7 million in PEMGARDA net product revenue, which marks a 22% growth compared to Q1…
Earnings Call Insights: Invivyd (IVVD) Q1 2026 MANAGEMENT VIEW * "We triggered our DECLARATION study upsizing in early April, and the recruitment speed into this additional upsized cohort occurred well faster than our internal expectations…
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This…
Major earnings expected before the bell on Thursday include: * Canadian Solar (CSIQ [https://seekingalpha.com/symbol/CSIQ]) * Bullish (BLSH [https://seekingalpha.com/symbol/BLSH]) * Intuitive Machines (LUNR [https://seekingalpha.com/symbol…
Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issuesResults allow for comparison to contemporary COVID-19 mRNA and p…
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on May 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 731,000 shares of its common st…
Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ growth stocks to buy and hold forever. On April 9, Invivyd announced significant progress in its REVOLUTION clinical program, specifically regarding VYD2311, a monoclonal antibody candid…
The S&P 500(SNPINDEX:^GSPC) rose 0.62% to 6,824.66, the Nasdaq Composite(NASDAQINDEX:^IXIC) climbed 0.83% to 22,822.42, and the Dow Jones Industrial Average(DJINDICES:^DJI) added 0.58% to 48,185.80 as stocks built on yesterday’s ceasefire-…
[Corona Virus covid-19 illustration] peterschreiber.media Invivyd (IVVD [https://seekingalpha.com/symbol/IVVD]) shares rose on Thursday after the Waltham, Massachusetts-based biotech announced progress in a late-stage trial for VYD2311, it…
National education campaign aims to educate Americans about antibodies and their role in immune healthCampaign centerpiece, AntibodiesforAnyBody.com, offers an interactive immune health wellnessassessment to empower people to better unders…
NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an aggregate of 1,083,750 shares of its com…
Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine Congress WashingtonPresentation titled “Developing mAb Therapies that Keep Pace with Rapidly Evolving…
Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has seen a significant 15% rise over the past year, with earnings expected to grow by 16% annually. In this context of fluctuating market conditions and pro…
Invivyd logo Key Points Invivyd has completed enrollment in the pivotal DECLARATION trial of VYD2311 and reiterates "mid‑year" guidance for results (2Q–3Q 2026); the trial includes a pre‑specified upsizing algorithm that could add roughly…
MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This qua…
Halozyme Therapeutics (HALO) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $2.15. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for non-recurring items. This…
Invivyd, Inc. (NASDAQ:IVVD) is one of the best penny stocks to buy in 2026. On January 8, Invivyd, Inc. (NASDAQ:IVVD) reported preliminary fourth-quarter 2025 net product revenue of $17.2 million from PEMGARDA (pemivibart), representing 25…
Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash equivalents of $226.7 million after raising ov…
Invivyd Inc. (NASDAQ:IVVD) is one of the best biotech penny stocks to buy according to analysts. On December 22, BTIG analyst Thomas Shrader initiated coverage of Invivyd with a Buy rating and $10 price target. BTIG maintained this stance…
Invivyd, Inc. was recently added to both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, increasing its presence among publicly traded biotech peers. This twin index inclusion can broaden Invivyd’s exposure…
(RTTNews) - Invivyd, Inc. (IVVD) has advanced its COVID-19 prevention portfolio with the launch of its pivotal Phase 3 DECLARATION trial of VYD2311, an investigational monoclonal antibody, alongside securing Fast Track designation from the…
(RTTNews) - Invivyd, Inc. (IVVD) on Tuesday said the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, the company's vaccine-alternative antibody candidate to prevent COVID-19. Programs with Fast Track…
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monocl…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Raymond James upgraded Cummins (CMI) to Outp…
Chaay_Tee / iStock via Getty Images Quick Read Friday’s triple witching expiration for options and futures helped the markets close the week on a solid note. The strong move higher by all the major indices may signal the beginning of a tra…
Invivyd Inc. (NASDAQ:IVVD) is one of the best multibagger penny stocks to buy right now. On November 24, the company selected VBY329 as a monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) in neonates, in…
NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m…
VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platformVBY329 meets Invivyd’s target profile of…
* Invivyd (IVVD [https://seekingalpha.com/symbol/IVVD]) priced [https://seekingalpha.com/pr/20310672-invivyd-announces-pricing-of-125-million-public-offering-of-common-stock-and-pre-funded] an underwritten public offering of 44M shares at…
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and,…
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the under…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change UTime Ltd. 897,372,188 0.045 0.035 0.0365 +0.0165 Aspire Biopharma Holding…